Micronoma News and Resources
News
FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer
In Brief This Week: Micronoma, Legend Biotech, Point Biopharma, AstraZeneca, Daiichi Sankyo, Takeda,
Read more at Precision Oncology News
FDA Grants Breakthrough Device Designation to OncobiotaLUNG Assay for Lung Cancer Detection
The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early...
Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection
Micronoma, the first biotech company offering early cancer detection with a microbiome-driven...
Announcements
Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, A Novel Liquid Biopsy Assay for Lung Carcinoma Detection
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven...
Micronoma to Provide Oncobiota Solution and Company Updates During JPM Life Science Conference Week 2023
December 14, 2022. SAN DIEGO, Calif.-- Micronoma, the first biotech company offering early cancer...
Research Finds Fungi Ubiquitous in Cancer with Diagnostic Implications
An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma...
Micronoma Makes Key VP of Business Development Hire
Todd Czerwinski will oversee the development and execution of market access, strategic...
Meet us at these
upcoming conferences
Winter Q-Bio Conference (Quantitative Biology), Puerto Rico. February 20-24, 2023.
Biocom's Global Life Science Partnering & Investor Conference, La Jolla, Ca. February 28-March 2, 2023.
SITC Spring Scientific Conference, Host Immunity in Cancer and Immunotherapy Response: From Discoveries to Holistic Precision Oncology, Blood Microbiome for Early Detection of Lung Cancer. Denver, Colorado. March 15 – 17, 2023.
AACR Annual Meeting, Orlando, Florida. Tuesday Apr 18, 2023: Increasing the Clinical Utility of Cell-Free DNA Testing.
Website Terms of Use, Privacy Policy, and Licenses
Micronoma, INC., CLIA #05D2253538
Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.
Contact Us
If you have questions or would like to learn more, please email us at info@micronoma.com or learn about joining our team at Careers.
Micronoma
6342 Ferris Square
San Diego, CA 92121